| Поле DC | Значение | Язык |
|---|
| dc.contributor.author | Spasov, A. A. | - |
| dc.contributor.author | Zvartau, E. E. | - |
| dc.contributor.author | Grechko, O. I. | - |
| dc.contributor.author | Eliseeva, N. V. | - |
| dc.contributor.author | Semenova, Yu. V. | - |
| dc.date.accessioned | 2022-05-05T07:13:27Z | - |
| dc.date.available | 2022-05-05T07:13:27Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205 / A.A. Spasov [et al.] // Research Results in Pharmacology. - 2020. - Vol.6, №3.-P. 59-65. - Doi: 10.3897/rrpharmacology.6.54558. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46602 | - |
| dc.description.abstract | The clinical use of kappa-opioid agonists, despite their lack of significant drug potential, is limited by the development of severe sedation, dysphoria, depression, and anhedonia. To this date, there are kappa-opioid receptor agonists lacking these side effects due to the selective activation of intracellular signal transmission pathways without p38-MAPK-kinase activation | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | dysphoria | ru |
| dc.subject | kappa-opioid receptor | ru |
| dc.subject | p38 MAPK-kinase | ru |
| dc.subject | butorphanol | ru |
| dc.subject | morphine | ru |
| dc.title | Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205 | ru |
| dc.type | Article | ru |
| Располагается в коллекциях: | Vol. 6, № 3
|
